![]() ![]() Zhang X, Xia P, Wang P, Yang J, Baird DJ.(2020) A Tiered Approach for Screening and Assessment of Environmental Mixtures by Omics and In Vitro Assays. (2022) CRISPR screen identified that UGT1A9 was required for bisphenols-induced mitochondria dyshomeostasis. Tian M#, Xia P#, Gou X, Yan L, Yu H, Zhang X.(2020) Highthroughput transcriptomics: An insight on the pathways affected in HepG2 cells exposed to nickel oxide nanoparticles. Saquib Q#, Xia P#, Siddiqui MA, Zhang J, Xie Y, Faisal M, Ansari SM, Alwathnani HA, Alatar AA, Al Khedhairy AA, Zhang X.(2020) Pathway-based assessment of single chemicals and mixtures by a high-throughput transcriptomics approach. Xia P, Zhang H, Peng Y, Shi W, Zhang X.(2016) Toxicogenomic Assessment of 6-OH-BDE47-Induced Developmental Toxicity in Chicken Embryos. Peng Y#, Xia P#, Zhang J, Villeneuve DL, Zhang J, Wang Z, Wei S, YuH, Zhang X.(Front Cover, ES&T 2016 Best Paper Award, ACS Editor’ Choice) (2016) Functional Toxicogenomic Assessment of Triclosan in Human HepG2 Cells Using Genome-Wide CRISPR-Cas9 Screening. Xia P, Zhang X, Xie Y, Guan M, Villeneuve DL, Yu H.(2017) Benchmarking Water Quality from Wastewater to Drinking Waters Using Reduced Transcriptome of Human Cells. Xia P, Zhang X, Zhang H, Wang P, Tian M, Yu H.(2018) A Reduced Transcriptome Approach to Assess Environmental Toxicants Using Zebrafish Embryo Test. Wang P#, Xia P#, Yang J, Wang Z, Peng Y, Shi W, Villeneuve DL, Yu H, Zhang X.(2020) Toxicogenomic Assessment of Complex Chemical Signatures in Double-Crested Cormorant Embryos from Variably Contaminated Great Lakes Sites. Xia P, Crump D, Chiu S, Chan HM, O'Brien JM.(2021) ToxChip PCR Arrays for Two Arctic-Breeding Seabirds: Applications for Regional Environmental Assessments. Zahaby Y#, Xia P#, Crump D, Provencher J, Thomas P, Pauli B, Braune B, Franckowiak R, Gendron M, Savard G, Sarma S, Mallory M, and O'Brien JM.(2021) Cross-Model Comparison of Transcriptomic Dose-Response of Short-Chain Chlorinated Paraffins. Xia P, Ying P, Fang W, Tian M, Shen Y, Ma C, Crump D, O'Brien JM, Shi W, Zhang X. ![]() INR can be used as a normalized indicator for intensity of anticoagulation therapy in China.The optimal anticoagulation intensity with INR range from 1.5 to 2.5 is safe and effective for Chinese patients with heart valve replacement, and there is no significant regional difference in the intensity of anticoagulation therapy. Anticoagulation-related morbidity and mortality rates were 0.67% and 0.15% Pty major hemorrhage morbidity and mortality rates were 0.25% and 0.13% Pty thromboembolism morbidity and mortality rates were 0.45% and 0.03% Pty.The mean dosage of warfarin daily dosage was (2.85☑.23) mg/d and INR value was 1.82☐.57.No significant regional difference in the intensity of anticoagulation therapy was noted during the study. In this multicenter prospective cohort study, the anticoagulation and monitoring strategy data was acquired from 25 773 in-hospital patients in 35 medical centers and 20 519 patients in outpatient clinic in 11 medical centers from January 1st, 2011 to December 31th, 2015.Īs for in-hospital patients, mean age of study population was (48.6☑1.2) years old main etiology of valve pathology was rheumatic (87.5%) origin among study cohort 94.8% of study population received mechanical valve implantation international normalized ratio (INR) monitoring (in all the study centers) and low-intensity anticoagulation strategy (31 hospitals chose target INR range of 1.5-2.5, and actual values of INR among 89.2% of 100 069 in-hospital monitoring samples were 1.5-2.5), with mean actual INR values of 1.84☐.53, and warfarin dosage of (2.82☐.93) mg/d were widely adopted among the study centers strategies of in-hospital warfarin administration were similar in all the study centers complication rates of low-intensity anticoagulation strategy were low in severe hemorrhage (0.02%), thrombosis (0.05%), and thromboembolism (0.05%) events, without anticoagulation-related death.As for 18 974 outpatient clinic patients, the follow-up rate was 92.47%, with a total of 30 012 patient-years (Pty). To investigate the optimal anticoagulation methods and monitoring strategy for Chinese patients undergoing heart valve replacement, which is potentially quite different from western populations.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |